Our year-long advocacy for an indefinite transition period of exemption/waiver to LDCs for pharmaceutical products has now ended with the final deal reached! Please see attached, the statement we have released critiquing the deal.
Yesterday 6th November, the WTO TRIPS Council adopted the decision to grant a 17-year transition period of exemption/waiver to LDCs regarding pharmaceutical products. We have expressed our disappointment and critique over this weak deal which is only 3 years more compared to the existing one (which ends this year) of 14 years granted in 2001. We had been advocating for an indefinite transition period of exemption/waiver, until a country exits the LDC category, given continual gross health challenges in LDCs.
(File) LDC Watch statement on ldc trips pharmaceutical 17yr extend – 170 kB (File Size)
